Hattie Hayes

Jennifer I. Lim, MD, FARVO, FASRS, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss her ASRS 2024 presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy."

The organization has secured £72.75 million for its new eye health center.

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular edema.

The award, supported by Oculis, will recognize outstanding contributions to retina research and will grant €30,000 for research support, and an additional €5,000 directly to the candidate.

The diagnostic and monitoring tools use artificial intelligence-based models.

The agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals).

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March.

At this year's ARVO meeting, the Eye Care Network spoke with Daniel Saben PhD, who is being awarded the Cogan Lecture at this year's event.

Elias Kahan speaks about his ARVO poster, "Contact specular microscopy reliably images the same location of the corneal epithelium."

Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

The European Commission is expected to make a decision about the application before the end of June.

Retina specialists Giuseppe Querques, MD, PhD, and Paolo Lanzetta, MD, debate at the Congress on Controversies in Ophthalmology

At this year's Congress on Controversies in Ophthalmology, keynote speaker Ursula Schmidt-Erfurth, MD, addressed the clinical use of artificial intelligence

The approval marks the first new steroid on the ophthalmic market in more than 15 years.

Sir Jules Thorn Charitable Trust's investment will support a state-of-the-art, eye health research facility, opening in 2027.

Dr. Jennifer Lim reveals new data on Angiopoietin-2 inhibition as a target for addressing nAMD and DME.

In conversation with Ophthalmology Times Europe, Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis.

Dr. Carl Regillo provided an overview of topline results and a deep dive into subgroup analyses of DAVIO 2 trial data.

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME.

A review of Ophthalmology Times Europe's most important content from throughout the year.

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

Charles Wykoff, MD, PhD, spoke with the Ophthalmology Times team about the GALE study looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.

Biocon’s YESAFILI is intended for treatment of a number of ocular conditions, including neovascular AMD, visual impairment due to myopic choroidal neovascularisation, visual impairment due to DME and visual impairment due to macular edema secondary to retinal vein occlusion.

The endorsement follows FDA approval in the United States this summer.

Mary Elizabeth Hartnett, MD, FACS, discussed the impact of blindness and vision loss on women in the United States.

The new range of pure and premixed gases are intended for medium-term use in retinal surgery.

Ali Erginay, MD, of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging."